A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro

Diagnostic Microbiology and Infectious Disease

Volumn 63, Issue 4, 2009, Pages 361-364

  Krishnan Natesan, Suganthini ^a   Manavathu, Elias K ^a   Alangaden, George J ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amphotericin B; Fungicidal; Kill curves; Mucor; Posaconazole; Rhizopus

Indexed keywords

AMPHOTERICIN B; POSACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MUCOR; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS; ZYGOMYCETES;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUCOR; RHIZOPUS; TIME FACTORS; TRIAZOLES; ZYGOMYCOSIS;

EID: 62249162867     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.12.013     Document Type: Article

References (21)

1. Dannaoui E., Meletiadis J., Mouton J.W., Meis J.F., and Verweij P.E. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51 (2003) 45-52
2. Dannaoui E., Mouton J.W., Meis J.F., and Verweij P.E. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob. Agents Chemother. 46 (2002) 1953-1959
3. Espinel-Ingroff A., Fothergill A., Ghannoum M., Manavathu E., Ostrosky-Ziechner L., Pfaller M., Rinaldi M., Schell W., and Walsh T. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M38-A document) for amphotericin B, itraconazole, posaconazole and voriconazole. J. Clin. Microbiol. (2005) 5243-5246
4. Goldani L.Z., and Sugar A.M. Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug. J. Antimicrob. Chemother. 33 (1994) 369-372
5. Greenberg R.N., Scott L.J., Vaughn H.H., and Ribes J.A. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr. Opin. Infect. Dis. 17 (2004) 517-525
6. Greenberg R.N., Mullane K., van Burik J.-A.H., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50 (2006) 126-133
7. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole antifungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58 (2004) 612-624
8. Kontoyiannis D.P., Wessel V.C., Bodey G.P., and Rolston K.V.I. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30 (2000) 851-856
9. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. 191 (2005) 1350-1359
10. Marco F., Pfaller M.A., Messer S.A., and Jones R.N. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 141 (1998) 73-77
11. Pagano L., Offidani M., Fianchi L., et al. Mucormycosis in hematologic patients. Haematologica 89 (2004) 207-214
12. Pitisuttithum P., Negroni R., Graybill J.R., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56 (2005) 745-755
13. Rex J.H., Alexander B.D., Andes D., Arthington-Skaggs B., Brown S.D., Chaturveli V., Espinel-Ingroff A., Ghannoum M.A., Knapp C.C., Motyl M.R., Ostrosky-Zeichner L., Pfaller M., Sheehan D.J., and Walsh T.J. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi (2008), Approved standard---2nd ed (M38-A2) Clinical and Laboratory Standards Institute (CLSI) Vol 28. No. 16
14. Ribes J.A., Vanover-Sams C.L., and Baker D.J. Zygomycetes in human disease. Clin. Microbiol. Rev. 13 (2000) 236-301
15. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41 (2005) 634-653
16. Sun Q.N., Fothergill A.W., McCarthy D.I., Rinaldi M.G., and Graybill J.R. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob. Agents Chemother. 46 (2002) 1581-1582
17. Sun Q.N., Najvar L.K., Bocanegra R., Loebenberg D., and Graybill J.R. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed mouse model. Antimicrob. Agents Chemother. 46 (2002) 2310-2312
18. Tobon A.M., Arango M., Fernandez D., and Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36 (2003) 1488-1491
19. Uchida K., Yokota N., and Yamaguchi H. In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents 18 (2001) 167-172
20. Van Cutsem J., and Boelaert J.R. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 36 (1989) 1061-1068
21. Van Cutsem J., Van Gerven F., Fransen J., and Janssen P.A. Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy 35 (1989) 267-272